{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:11:16Z","timestamp":1790187076871,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["823B2086"],"award-info":[{"award-number":["823B2086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273640"],"award-info":[{"award-number":["82273640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","award":["L244091"],"award-info":[{"award-number":["L244091"]}],"id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","award":["TYJJ202402"],"award-info":[{"award-number":["TYJJ202402"]}],"id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220005"],"award-info":[{"award-number":["20720220005"]}],"id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}],"id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.lanwpc.2025.101671","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:54:50Z","timestamp":1756274090000},"page":"101671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18\u201326 years: three-year follow-up data from a randomised clinical trial"],"prefix":"10.1016","volume":"62","author":[{"given":"Guo-Hua","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4064","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong-Xin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Xian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-8889","authenticated-orcid":false,"given":"Wei-Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-3056","authenticated-orcid":false,"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Shao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2025.101671_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.lanwpc.2025.101671_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanwpc.2025.101671_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanwpc.2025.101671_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lanwpc.2025.101671_bib5","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper, December 2022","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.lanwpc.2025.101671_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/vaccines12010004","article-title":"The global demand and supply balance of the human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer","volume":"12","author":"Malvolti","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanwpc.2025.101671_bib10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S1473-3099(23)00275-X","article-title":"Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18\u201326 years in China: a randomised blinded clinical trial","volume":"23","author":"Zhu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanwpc.2025.101671_bib11","article-title":"Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6\/11\/16\/18\/31\/33\/45\/52\/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial","volume":"34","author":"Chu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanwpc.2025.101671_bib12","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.scib.2023.09.020","article-title":"Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6\/11\/16\/18\/31\/33\/45\/52\/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial","volume":"68","author":"Hu","year":"2023","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.lanwpc.2025.101671_bib13","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lanwpc.2025.101671_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2377903","article-title":"Long-term effectiveness of the nine-valent human papillomavirus vaccine: interim results after 12 years of follow-up in Scandinavian women","volume":"20","author":"Kjaer","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2025.101671_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/v8040107","article-title":"Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirus","volume":"8","author":"Nie","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.lanwpc.2025.101671_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1908059","article-title":"Review of long-term immunogenicity following HPV vaccination: gaps in current knowledge","volume":"18","author":"Hoes","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2025.101671_bib17","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanwpc.2025.101671_bib18","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.vaccine.2024.02.077","article-title":"Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9\u201314 years of age: interim analysis from a phase 3 clinical trial","volume":"42","author":"Zaman","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2025.101671_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127015","article-title":"Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9\u201314 years: a randomized and open-label clinical trial","volume":"55","author":"Xie","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2025.101671_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1473-3099(25)00031-3","article-title":"Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9\u201314 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial","volume":"25","author":"Agbenyega","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanwpc.2025.101671_bib21","article-title":"Naturally acquired HPV antibodies against subsequent homotypic infection: a large-scale prospective cohort study","volume":"13","author":"Yao","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanwpc.2025.101671_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jncimonographs\/lgae042","article-title":"A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination","volume":"2024","author":"Malvi","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.lanwpc.2025.101671_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2025.101671_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lanwpc.2025.101671_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100486","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: an updated systematic review of evidence from clinical trials","volume":"19","author":"Whitworth","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanwpc.2025.101671_bib26","author":"Zhang"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266660652500210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266660652500210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:33:14Z","timestamp":1772919194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266660652500210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"alternative-id":["S266660652500210X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101671","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18\u201326 years: three-year follow-up data from a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101671"}}